company background image
IMMP logo

Immutep NasdaqGM:IMMP Stock Report

Last Price

US$1.84

Market Cap

US$270.0m

7D

-12.0%

1Y

-2.1%

Updated

21 Nov, 2024

Data

Company Financials +

IMMP Stock Overview

A late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. More details

IMMP fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Immutep Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Immutep
Historical stock prices
Current Share PriceAU$1.84
52 Week HighAU$3.34
52 Week LowAU$1.66
Beta1.92
11 Month Change-5.64%
3 Month Change-24.28%
1 Year Change-2.13%
33 Year Change-48.17%
5 Year Change9.52%
Change since IPO-95.42%

Recent News & Updates

Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients

Nov 15

Recent updates

Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients

Nov 15

Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs

Jul 15

Immutep: Realizing The Expected Catalysts, With More To Come

May 01

Immutep stock climbs on FDA fast track status for eftilagimod to treat lung cancer subtype

Oct 04

Immutep secures €1.8M cash in French government's research tax credit

Sep 23

Immutep gets Japanese patent for immunotherapy eftilagimod alpha combo

Aug 30

Immutep gets Japanese patent related to autoimmune disease drug candidate IMP761

Jul 06

Immutep: Australian Immune-Focused Company, Pureplay LAG3 Player

Jun 12

Immutep - LAG3 Checkpoint Receives First FDA Approval; Positive For This LAG3 Pure Play

Mar 21

Immutep expands the evaluation of efti into a triple combination therapy, shares down 12%

Jun 21

Immutep reveals anti-LAG-3 research program

Jun 08

Immutep jumps 9% on Chinese patent for efti in chemo-immunotherapy combination

May 26

Immutep completes recruitment in efti mid-stage study in head & neck cancer

Jan 07

Immutep secures U.S. patent for Eftilagimod Alpha

Dec 29

Shareholder Returns

IMMPUS BiotechsUS Market
7D-12.0%-6.5%-1.0%
1Y-2.1%14.6%30.3%

Return vs Industry: IMMP underperformed the US Biotechs industry which returned 14.6% over the past year.

Return vs Market: IMMP underperformed the US Market which returned 30.3% over the past year.

Price Volatility

Is IMMP's price volatile compared to industry and market?
IMMP volatility
IMMP Average Weekly Movement7.4%
Biotechs Industry Average Movement9.7%
Market Average Movement6.2%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: IMMP has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: IMMP's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1987n/aMarc Voigtwww.immutep.com

Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma.

Immutep Limited Fundamentals Summary

How do Immutep's earnings and revenue compare to its market cap?
IMMP fundamental statistics
Market capUS$270.03m
Earnings (TTM)-US$27.82m
Revenue (TTM)US$2.50m

107.9x

P/S Ratio

-9.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IMMP income statement (TTM)
RevenueAU$3.84m
Cost of RevenueAU$41.55m
Gross Profit-AU$37.70m
Other ExpensesAU$5.01m
Earnings-AU$42.72m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.029
Gross Margin-981.42%
Net Profit Margin-1,111.87%
Debt/Equity Ratio0.5%

How did IMMP perform over the long term?

See historical performance and comparison